FindMyKOL
Clinical trialNCT05432193TerminatedPhase 1Interventional

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

SponsorPOINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyEnrollment20CholangiocarcinomaColorectal CancerEsophageal CancerHead and Neck Squamous Cell CarcinomaMelanoma (Skin)Pancreatic Ductal Adenocarcinoma+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This Phase 1 study will evaluate the safety and tolerability of \[Ga-68\]-PNT6555 and \[Lu-177\]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • University Health Network - Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Chum - Centre Hospitalier de L'Université de Montréal

    Montreal, Quebec, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

United States
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

[Ga-68]-PNT6555[Lu-177]-PNT6555
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 Jul 2022
Primary completion
10 Nov 2023
Completion
2 Oct 2024
Last update posted
25 Jun 2025
Registered enrollment
20
Registry id
NCT05432193
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.